Drugs / Bivalent Oral Polio Vaccine
Bivalent Oral Polio Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06920069 | May 2025 → Jul 2030 expected | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01813604 Comparator | Nov 2012 → Nov 2013 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01559636 Comparator | Aug 2012 → Aug 2013 | diarrheal disease, hyperimmunoglobulin syndrome, poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent Oral Polio Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01813604 ↗ |
| Known as | bivalent 1+3 OPV | “bivalent 1+3 OPV (bOPV) will replace trivalent OPV (tOPV)” PMID 27085172 ↗ Apr 2016 |
| Known as | bOPV | “bivalent 1+3 OPV (bOPV) will replace trivalent OPV (tOPV)” PMID 27085172 ↗ Apr 20161“bivalent oral polio vaccine (bOPV)” NCT01813604 ↗ |
| Known as | bOPV 1,3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06920069 ↗ |
| Modality | Vaccine | “vaccine given during immunization campaigns” NCT01559636 ↗ |
| Route | Oral | “bivalent oral polio vaccine” NCT01559636 ↗ |